AL Amyloidosis VA Claims: Agent Orange, Ratings and Back Pay

Veterans with qualifying herbicide exposure and a confirmed AL amyloidosis diagnosis can receive presumptive VA service connection without proving that Agent Orange caused the disease. VA rates service-connected AL amyloidosis at 100% under Diagnostic Code 7717 and claims commonly depend on confirming the AL subtype, qualifying exposure, and the correct effective date.

• AL amyloidosis has been an Agent Orange presumptive condition since May 7, 2009. Once qualifying herbicide exposure and the AL diagnosis are established, a separate nexus opinion is generally unnecessary.
• VA assigns a flat 100% rating under Diagnostic Code 7717. The rule does not call for a routine follow-up examination to reevaluate that percentage.
• The amyloidosis subtype must be clear. AL amyloidosis receives the herbicide presumption, while ATTR and other forms do not automatically qualify under the same rule.
• Substantial back pay is a possibility when VA denied or left pending an earlier AL amyloidosis claim involving a qualifying Vietnam veteran or survivor.
• Camp Lejeune and other toxic exposure claims need medical evidence of causation

When Is AL Amyloidosis a Presumptive VA Disability?

VA added AL amyloidosis to its Agent Orange presumptive list of conditions effective May 7, 2009. A veteran with qualifying herbicide exposure and a confirmed AL amyloidosis diagnosis generally does not need to submit a medical opinion proving that Agent Orange caused the disease.

AL amyloidosis has no manifestation deadline under the Agent Orange rules. A veteran who served in a covered location in 1969 and received the diagnosis in 2026 may still qualify. VA’s one-year manifestation requirements for conditions such as chloracne and early-onset peripheral neuropathy do not apply to AL amyloidosis.

The presumption covers only the medical connection and a disability claim will still require evidence establishing the diagnosis and qualifying exposure. Veterans without qualifying Agent Orange exposure may have another path: AL amyloidosis claims have been granted based on Camp Lejeune water contamination, other toxic exposures and secondary service connection when medical evidence supported the connection.

Which Types of Amyloidosis Does VA Recognize?

AL amyloidosis is a plasma-cell disorder in which abnormal light-chain proteins misfold and collect in organs, nerves and other tissue. Those deposits can interfere with how the heart, kidneys, liver, gastrointestinal system and peripheral nerves function.

The VA rating schedule also calls AL amyloidosis “primary amyloidosis.” Medical records may use “amyloid light-chain amyloidosis” or “light-chain amyloidosis.” Those terms can describe the same disease process.

On the other hand, medical records that say only “amyloidosis” or “cardiac amyloidosis” may leave VA unable to determine whether the veteran has the AL subtype covered by the Agent Orange presumption. The Agent Orange presumption specifically covers AL amyloidosis. ATTR amyloidosis involves transthyretin proteins and follows a different medical and legal path.

Is AL Amyloidosis a Cancer?

AL amyloidosis is generally classified as a plasma-cell disorder rather than a separate cancer diagnosis. It develops from abnormal plasma cells, the same cell family involved in multiple myeloma, and the two conditions can occur together.

Their shared plasma-cell biology may also become relevant in a direct or secondary service-connection opinion, but the relationship between the two diseases does not prove that one caused or aggravated the other in a particular veteran.

The same caution applies to monoclonal gammopathy of undetermined significance, or MGUS. MGUS, multiple myeloma and AL amyloidosis can arise from abnormal plasma-cell activity, but VA still needs the correct diagnosis and medical evidence identifying the relationship among the conditions.

What Does the Research Show?

The Agent Orange presumption reflects research associating herbicide exposure with amyloidosis. One large study (Yi et al. 2014) examined 111,726 Korean veterans who served in Vietnam and used national health insurance claims data covering January 2000 through September 2005.

After the researchers adjusted for other variables, the group with higher estimated Agent Orange exposure had greater odds of amyloidosis than the lower-exposure group. The reported odds ratio was 3.02. The study examined amyloidosis as a category rather than limiting the analysis to confirmed AL cases, so it supports the broader association without resolving every subtype question.

How Rare Is AL Amyloidosis?

AL amyloidosis affects a small share of the population. A U.S. claims-data study estimated annual incidence between 9.7 and 14 cases per million person-years from 2007 through 2015. Estimated prevalence increased from 15.5 cases per million to 40.5 per million during the same period.

Its rarity can create practical problems in a VA claim. General treatment notes may not explain the subtype clearly, and a rater may see references to heart or kidney amyloid without receiving the pathology and light-chain evidence needed to confirm AL amyloidosis.

How Does VA Rate AL Amyloidosis?

VA rates service-connected AL amyloidosis at 100% under Diagnostic Code 7717 in 38 C.F.R. § 4.117. The code provides one evaluation rather than a tiered schedule based on symptoms or treatment, because AL amyloidosis is progressive and can involve several organs.

Older rating decisions may look different. Before Diagnostic Code 7717 took effect on March 9, 2012, VA had no dedicated code for AL amyloidosis and commonly rated the disease by analogy to non-Hodgkin’s lymphoma under a built-up code such as 7799-7715. An older award should be reviewed to determine which code VA used and whether later changes affected the evaluation.

Can VA Reduce a 100% AL Amyloidosis Rating?

Diagnostic Code 7717 does not contain a temporary treatment period or a scheduled reevaluation provision. VA explained when it created the code that routine follow-up examinations were unnecessary because of the disease’s progressive nature and prognosis.

A veteran rated at 100% for AL amyloidosis generally does not need TDIU to receive the basic 100% compensation rate. TDIU may still require review when another single service-connected disability independently causes unemployability and could affect entitlement to special monthly compensation.

Back Pay for AL Amyloidosis

AL amyloidosis is a covered herbicide disease under the Nehmer rules, which may allow qualifying Vietnam veterans and survivors to receive benefits based on an earlier claim filed before the May 7, 2009, presumptive date.

Under 38 C.F.R. § 3.816, VA may use the date of an earlier claim when it denied compensation for the same covered herbicide disease between Sept. 25, 1985, and May 3, 1989. Similar rules apply when the claim was pending on May 3, 1989, or was filed between that date and May 7, 2009.

The effective date is generally the later of the date VA received the earlier claim or the date the disability arose, subject to the regulation’s additional provisions. A claim filed within one year after separation may qualify for an effective date beginning the day after service.

The earlier record does not always have to use the exact words “AL amyloidosis.” Section 3.816 allows VA to treat a prior decision as a denial of the same covered disease when the condition described in the earlier record can reasonably be construed as the same disability.

What if the Veteran Was Exposed Outside Vietnam?

Nehmer has a specific class definition and should not be assumed to apply to every veteran who qualifies for an Agent Orange presumption. Thailand, Korean DMZ, C-123 and other exposure cases may involve different effective-date rules even though AL amyloidosis itself remains presumptive.

For example, in A25030813, decided April 3, 2025, the Board of Veterans’ Appeals found that a veteran had been exposed to herbicides at Udorn Royal Thai Air Force Base and assigned an earlier effective date of June 7, 2018 for an existing AL amyloidosis award. That decision is nonprecedential, but it shows that effective date disputes can arise from exposure findings, claim history and the evidence VA had at different stages of the case.

Can a Survivor Receive Retroactive AL Amyloidosis Benefits?

A surviving spouse, child or parent of a deceased Vietnam veteran may qualify as a Nehmer class member when AL amyloidosis caused the veteran’s death. The same retroactive framework can apply to a qualifying survivor’s DIC claim.

A survivor should obtain the veteran’s prior rating decisions, pending claims, medical records and death records before accepting the effective date VA assigned. Those records may show an earlier claim that VA should have considered.

What Evidence Does VA Need for an AL Amyloidosis Claim?

An Agent Orange AL amyloidosis claim usually needs two core forms of proof: medical evidence confirming the AL subtype and service evidence establishing qualifying herbicide exposure. Claims involving another toxic exposure also need competent medical evidence connecting that exposure to the disease.

Pathology and Light-Chain Typing

The medical file should contain the biopsy report confirming amyloid deposits and the testing that identifies the deposits as light-chain amyloid. Hematology or oncology records should use a clear diagnosis such as “AL amyloidosis” or “amyloid light-chain amyloidosis.”

A chart that says only “amyloidosis” may leave the subtype unresolved. The same concern applies to “cardiac amyloidosis,” which identifies the affected organ but not necessarily the protein responsible for the deposits.

Specialist and Treatment Records

Chemotherapy, stem cell transplant, hematology, cardiology, nephrology and neurology records can establish that the disease remains current and show which organs it affects. These records also help separate AL amyloidosis from ATTR amyloidosis, multiple myeloma, MGUS and other plasma-cell disorders.

VA may already have some of those records, but veterans should confirm that the claims file contains the pathology and specialist evidence rather than relying on a brief primary care summary.

Service and Exposure Records

Qualifying herbicide exposure may appear in the DD-214, personnel file, unit history, deck logs, assignment orders, performance evaluations or a prior VA decision. Thailand, Blue Water Navy, Korean DMZ and C-123 cases often require more detailed records establishing the precise location and dates.

Hill & Ponton’s guide to building the exposure record explains the kinds of service evidence that can support an Agent Orange claim when the DD-214 does not resolve the question.

Medical Nexus Evidence

A veteran with a confirmed AL diagnosis and qualifying Agent Orange exposure generally does not need a nexus letter. The presumption handles causation.

A medical opinion becomes necessary when the veteran relies on Camp Lejeune water, burn pits, solvents, fumes or another exposure that does not carry an AL amyloidosis presumption. The opinion should address the veteran’s specific exposure history, competing causes and the reasoning in any negative VA examination.

A reasoned nexus opinion carries more weight than a conclusion that merely says toxic exposure “could” have caused the disease. The physician should identify the evidence reviewed and explain why the connection reaches VA’s “at least as likely as not” standard.

Evidence of Organ Damage

Cardiac, renal, neurological, liver and gastrointestinal records can document the full disease burden and support any separate organ claims.

Lay and buddy statements may also support service locations, duties, symptom onset and daily limitations. They cannot establish the amyloidosis subtype without competent medical evidence.

When the positive and negative evidence on a material issue is in approximate balance, 38 C.F.R. § 3.102 requires VA to resolve reasonable doubt in the claimant’s favor.

What Do BVA Decisions Show About Agent Orange AL Amyloidosis Claims?

Hill & Ponton analyzed Board of Veterans’ Appeals decisions from 2021 through December 2025 and identified 14 Agent Orange or herbicide AL amyloidosis issues. Five herbicide claims were granted, four were denied and five were remanded. This is a small sample and does not represent VA’s overall approval rate, but the decisions can show where these claims often succeed or fail.

Grants Based on Qualifying Herbicide Exposure

In 23002961, decided Jan. 18, 2023, the Board found that service at Camp Howze and Camp Casey placed the veteran near the Korean DMZ. Presumed herbicide exposure and a confirmed diagnosis supported service connection for AL amyloidosis.

In A22013424, decided July 15, 2022, Navy records placed the veteran aboard the USS Franklin D. Roosevelt in Vietnam’s territorial waters. The Board granted the AL amyloidosis claim under the herbicide presumption.

The Board also granted AL amyloidosis in A25075228, decided Sept. 5, 2025, based on qualifying service in Thailand. Once the Board established covered exposure and the diagnosis, none of these veterans needed a separate opinion proving that Agent Orange caused the disease.

Denials Based on a Missing Diagnosis

Presumed exposure cannot substitute for medical evidence identifying the disease: three of the four denials in Hill & Ponton’s analysis involved a failure to establish the AL amyloidosis diagnosis.

In 21035495, decided June 9, 2021, VA conceded herbicide exposure and granted Type 2 diabetes in the same decision. The Board denied AL amyloidosis because the record did not establish that the veteran had the disease.

The Board reached a similar conclusion in 22035794, decided June 21, 2022. It found that the evidence weighed against an AL amyloidosis diagnosis at any time during the claim period.

In 23002198, decided Jan. 12, 2023, the Board denied AL amyloidosis for lack of a current diagnosis while granting urinary, bladder, prostate and kidney claims arising from the same presumed exposure.

How Can AL Amyloidosis Be Service Connected Without the Agent Orange Presumption?

Veterans without qualifying Agent Orange service may pursue direct or secondary service connection. These claims depend more heavily on medical evidence because no legal presumption supplies the connection.

Camp Lejeune Water Contamination

VA presumes that veterans, reservists and National Guard members who served at Camp Lejeune or Marine Corps Air Station New River for at least 30 cumulative days from Aug. 1, 1953, through Dec. 31, 1987, were exposed to specified contaminants in the water supply.

AL amyloidosis is not among the diseases VA automatically associates with Camp Lejeune exposure. A veteran can still establish direct service connection with competent medical evidence linking the disease to the contaminated water.

Hill & Ponton’s Board review identified two grants involving Camp Lejeune, but those decisions apply only to the individual facts.

In 23041073, decided July 27, 2023, the Board granted AL amyloidosis and chronic kidney failure secondary to it. A private oncologist compared AL amyloidosis with multiple myeloma, a Camp Lejeune presumptive disease, and identified a factual flaw in VA’s negative opinion. The VA examiner had attributed the disease to MGUS even though the veteran did not have an MGUS diagnosis.

In 21015927, decided March 18, 2021, the Board granted service connection for the veteran’s cause of death. It weighed three favorable private medical opinions against one negative VA opinion and found the evidence evenly balanced.

Other Toxic Exposures

AL amyloidosis may also be claimed based on solvents, fumes or another toxic exposure risk activity. A proper TERA opinion should address the veteran’s total potential exposure and the combined effect of all supported toxic exposures raised by the record.

In A25046542, decided May 23, 2025, the Board remanded an AL amyloidosis claim because VA’s opinions had not addressed several alleged exposures. Those included fumes and solvents, heat stress during Southwest Asia service and a reported rocket attack.

Medical opinions in these cases need more than a general statement that toxic chemicals can cause disease. The analysis should identify the substances, explain the likely exposure route and dosage when the record supports it, address competing causes and apply the medical literature to the veteran’s disease.

Secondary Service Connection

Under 38 C.F.R. § 3.310, VA may grant service connection when an established service-connected disability causes or aggravates another condition.

Multiple myeloma and AL amyloidosis involve related plasma-cell processes, but their biological relationship does not automatically establish secondary service connection. A veteran claiming AL amyloidosis secondary to service-connected multiple myeloma needs a medical opinion explaining causation or aggravation in that particular case.

Additional Compensation for AL Amyloidosis

A veteran rated at 100% for AL amyloidosis could be eligible for special monthly compensation, which pays above the 100% rate. For instance, aid and attendance could be possible when AL amyloidosis leaves the veteran needing regular help with bathing, dressing, medication, or other daily activities.

The housebound benefit may apply when a veteran has one disability rated at 100% and additional, separate service-connected disabilities independently ratable at 60%, or when service-connected disabilities leave the veteran permanently housebound. Since AL amyloidosis can satisfy the single 100% requirement, the remaining question is whether separately rated organ damage or other service-connected disabilities meet the additional criteria.

AL amyloidosis can damage the heart, kidneys, peripheral nerves, liver and gastrointestinal system. Medical evidence should identify each affected organ and explain whether the disease caused or aggravated a separately diagnosable condition. VA cannot compensate the same symptom or functional loss twice: a separate rating requires a distinct disability and distinct manifestations under another diagnostic code.

What Can Survivors Claim If a Veteran Died of AL Amyloidosis?

A surviving spouse, qualifying child or dependent parent may receive Dependency and Indemnity Compensation when a service-connected disability caused or substantially contributed to the veteran’s death.

Under 38 C.F.R. § 3.312, a disability can qualify as the principal cause when it was the immediate or underlying cause of death or was medically related to that cause. A contributory cause must have played a substantial or material role rather than sharing a casual association with death.

AL amyloidosis does not always appear by name on the death certificate. Cardiac failure, kidney failure, arrhythmia or another organ complication may appear instead.

The Board addressed that problem in 21015927. The death certificate listed cardiac arrest due to end-stage heart failure, and no autopsy had been performed. A private physician connected the fatal cardiac disease to amyloidosis, and the Board found AL amyloidosis was the principal cause of death.

A survivor may establish service connection for the first time even when VA never granted the veteran’s claim during life. The record still needs to establish the AL diagnosis, qualifying exposure or another service connection theory, and the disease’s role in the death.

Prior claims and denials should be reviewed before a survivor accepts the effective date VA assigned, especially when the veteran or survivor filed an earlier AL amyloidosis or cause-of-death claim.

Get Help with a Denied AL Amyloidosis VA Claim

AL amyloidosis appeals often involve a disputed subtype, incomplete exposure evidence, an inadequate medical opinion or an effective date that overlooks an earlier claim. Organ damage and cause-of-death evidence may create additional issues for veterans and survivors.

Hill & Ponton represents veterans and surviving family members in appeals of denied VA disability and DIC claims. A veteran or survivor whose AL amyloidosis claim was denied, underrated or assigned the wrong effective date may request a free case evaluation to review the available appeal options.